β1-adrenergic Receptor (β1AR) Autoantibodies Endogenously Bias β1AR Signaling

Maradumane Mohan,Chia-Feng Liu,Khuraijam Dhanachandra Singh,Sadashiva S. Karnik,Wai Hong Tang,Sathyamangla V. Naga Prasad

DOI: https://doi.org/10.1016/j.cardfail.2023.10.076

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Autoimmune response to self-antigens results in autoantibodies (AAbs), wherein AAbs against extra cellular loop 2 (ECL2) of β1AR is known to underlie dilated cardiomyopathy (DCM). Contrarily, recent studies show that patients with β1AR AAbs belonging to the IgG3 subclass have beneficial outcomes. However, the signaling mechanisms that underlie the beneficial outcomes are not well understood. Hypothesis IgG3(+) β1AR AAbs facilitates uniquely biased β1AR signaling in response to β-blockers. Methods Since IgG3(+) β1AR AAbs are associated with favorable patient outcomes, in silico studies were conducted to evaluate the interaction between the IgG3(+) antibody and the known structure of β1AR. In silico epitope prediction suggested that the extracellular loop 1 (ECL1) could be a potential epitope, wherein binding by IgG3(+) AAbs at ECL1 could facilitate unique biased signaling in response to β-blockers. Peptides representing human β1AR ECL 1 was synthesized and antibodies targeting the human β1AR ECL 1 was generated by immunizing the mice. HEK 293 cells expressing human β1AR were pre-treated with serum containing antibodies against ECL 1 of β1AR followed by either β1AR selective agonist dobutamine (DOB) or β-blocker metoprolol stimulation. Downstream β1AR signaling was measured by cAMP generation. To test for specificity of ECL1 in the modulating β1AR responses, the cells were incubated with ECL 1 peptides along with antibodies against ECL1 of human β1AR as competitors and cAMP generation assessed following metoprolol. Results Treatment of human β1AR expressing HEK 293 cells with serum from mouse immunized with ECL1 of human β1AR showed no baseline changes in the cAMP generation. However, pretreatment of these cells with ECL1 antibodies followed by stimulation with DOB surprisingly showed marked reduction in cAMP generation in contrast to adjuvant controls which showed significant increase in cAMP. While, treatment of these ECL1 antibody pretreated cells with metoprolol unexpectedly resulted in cAMP generation which is blocked in the adjuvant controls. This shows that antibodies against the ECL1 of human β1AR binds to the β1AR and is able to allosterically modulate downstream signaling mediated by agonist (DOB) or β-blocker (metoprolol) as at baseline it does not alter β1AR function. To validate that antibodies against the ECL1 of human β1AR allosterically modulates metoprolol signaling, the cells were also pre-treated with competing doses of ECL1 peptide followed by metoprolol treatment. Consistent with our hypothesis, incubation with ECL1 peptide remarkably blocked cAMP generation in response to metoprolol. This shows that antibody binding to the ECL1 of human β1AR mediates this unique signaling in response to metoprolol wherein, a traditionally cAMP blocking β-blocker metoprolol now mediates cAMP generation. Conclusions These observations suggest that the allosteric binding of β1AR ECL1 by the antibodies mediates unexpected downstream signal that could underlie the benefits observed in the patients harboring IgG3(+) AAbs. Mechanisms underlying this unique allosteric modulation will be discussed in our presentation.

cardiac & cardiovascular systems